Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14143792 | 0.88 | FFAR1 (0.50) | FFAR1FFAR4NPSR1KEAP1THRA | |
| SCHEMBL22190396 | 0.87 | MAPK1 (0.55) | FFAR1FFAR4NPSR1RXRARXRB | |
| SCHEMBL22088079 | 0.86 | FFAR1 (0.49) | FFAR1FFAR4NPSR1KEAP1THRA | |
| SCHEMBL17705230 | 0.86 | THRA (0.50) | FFAR1FFAR4NPSR1KEAP1THRA | |
| SCHEMBL12834744 | 0.86 | FFAR1 (0.49) | FFAR1FFAR4NPSR1KEAP1THRA | |
| SCHEMBL28045328 | 0.85 | MAPT (0.55) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL28030638 | 0.84 | KMT2A (0.46) | FFAR1FFAR4NPSR1TPMT | |
| SCHEMBL23599377 | 0.83 | FFAR1 (0.50) | FFAR1FFAR4THRATHRB | |
| SCHEMBL5670212 | 0.83 | KEAP1 (0.64) | FFAR1FFAR4NPSR1KEAP1THRA | |
| SCHEMBL9632300 | 0.82 | ALDH1A1 (0.54) | FFAR1FFAR4THRATHRBTPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102307860-A | GPR120 receptor agonists and uses thereof | METABOLEX INC | 2012-01-04 | — | — | CN | claimed |
| US-20250172566-A1 | SACCHARIDE SENSING SYSTEMS | Carbometrics Limited (GB) | 2025-05-29 | — | — | US | disclosed |
| EP-4469803-A1 | SACCHARIDE SENSING SYSTEMS | Carbometrics Limited (GB) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144240-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES AND USES THEREOF | NOVO NORDISK RESEARCH CENTRE OXFORD LIMITED (GB) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144545-A1 | SACCHARIDE SENSING SYSTEMS | Carbometrics Limited (GB) | 2023-08-03 | — | — | WO | disclosed |
| CN-113321640-B | Indole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-06-09 | — | — | CN | disclosed |
| CN-109111427-B | Indole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-06-02 | — | — | CN | disclosed |
| WO-2020139636-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| CN-106414434-A | Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes | 詹森药业有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-105209444-A | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| CN-102958914-B | 1-phenyl substituted heterocyclic derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD | 2015-05-27 | — | — | CN | disclosed |
| CN-102307860-A | GPR120 receptor agonists and uses thereof | METABOLEX INC | 2012-01-04 | — | — | CN | disclosed |
| US-7012138-B1 | Chiral polysaccharide esters, one of the methods for preparing them and their uses for obtaining optically enriched acids or for chiral chromatography | UNIVERSITE DE DROIT D'ECONOMIE ET DES SCIENCES D'AIZ-MARSEILLE (FR) | 2006-03-14 | — | — | US | disclosed |
| EP-1135417-B1 | POLYSACCHARIDE CHIRAL ESTERS, ONE OF THE METHODS FOR PREPARING THEM AND THEIR USES FOR OBTAINING OPTICALLY ENRICHED ACIDS OR CHIRAL CHROMATOGRAPHY | UNIV DROIT D ECONOMIE ET DES S (FR) | 2003-06-25 | — | — | EP | disclosed |
| EP-1135417-A1 | POLYSACCHARIDE CHIRAL ESTERS, ONE OF THE METHODS FOR PREPARING THEM AND THEIR USES FOR OBTAINING OPTICALLY ENRICHED ACIDS OR CHIRAL CHROMATOGRAPHY | Universite De Droit, D'Economie et des Sciences D'Aix-Marseille (FR) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032638-A1 | POLYSACCHARIDE CHIRAL ESTERS, ONE OF THE METHODS FOR PREPARING THEM AND THEIR USES FOR OBTAINING OPTICALLY ENRICHED ACIDS OR CHIRAL CHROMATOGRAPHY | UNIVERSITE DE DROIT, D'ECONOMIE ET DES SCIENCES D'AIX-MARSEILLE (FR) | 2000-06-08 | — | — | WO | disclosed |
| EP-0393668-B1 | Method of preparation of benzaldehyde dialkyl acetals and new benzaldehyde dialkyl acetals | BASF AG (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0393668-A2 | Method of preparation of benzaldehyde dialkyl acetals and new benzaldehyde dialkyl acetals | BASF Aktiengesellschaft (DE) | 1990-10-24 | — | — | EP | disclosed |
| US-4544450-A | Electrochemical process for the synthesis of organic compounds | ANIC S.P.A. (IT) | 1985-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250172566-A1 | SACCHARIDE SENSING SYSTEMS | GALE, SLC2A8, SLC2A4 | FFAR1 2248/4885FFAR4 1894/4885NPSR1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.